CLINICAL TRIALS STEMMING FROM OUR LAB WORK

Clinical Trials Stemming From Our Lab Work

A Multi-Center Study of Arlo-Cel in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT04674813; Dana-Farber Cancer Institute PI Omar Nadeem et al ASH 2024
Multi-center phase I of GPRC5D-Targeted CARs

G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted Chimeric Antigen Receptor (CAR) Modified T Cells For The Treatment Of Multiple Myeloma
NCT04555551; Mailankody S PI et al NEJM 2022
Phase I single center study at Memorial Sloan Kettering Cancer Center of MCARH109

A Study of CC-98633, BCMA-Targeted Chimeric Antigen Receptor (CAR) T Cells, In Subjects With Relapsed And/or  Refractory Multiple Myeloma
NCT04394650; Megala Costa L et al ASH 2022
Multi-center phase I of BCMA-Targeted CARs using NEX-T manufacturing

​GPRC5D Antibody Based Therapies
Pre-clinical 
Being Developed by Sanofi Link here

Study Evaluating The Safety And Efficacy Of JCARH125 In Subjects With Relapsed And/or Refractory Multiple Myeloma (EVOLVE)
NCT03430011; Mailankody S et al ASH 2018a; Mailankody S et al ASCO 2020
Multi-center phase II study of Orvacabtagene autoleucel (formerly JCARH125)

BCMA Targeted CAR T Cells With Or Without Lenalidomide For The Treatment Of Multiple Myeloma
NCT03070327; Mailankody S et al ASH 2018b
Phase I single center study at Memorial Sloan Kettering Cancer Center of MCARH171

Immunotherapy With BCMA CAR-T Cells In Treating Patients With BCMA Positive Relapsed Or Refractory Multiple Myeloma
NCT03338972; Green D et al ASH 2018; Green D et al ASH 2019
Phase I single center study at Fred Hutchinson Cancer Research Center using FCARH143

BCMA-Specific CAR T-Cells Combined With A Gamma Secretase Inhibitor (JSMD194) To Treat Relapsed Or Persistent Multiple Myeloma
​NCT03502577; Cowan A et al ASH 2019
Phase I single center study at Fred Hutchinson Cancer Research Center using FCARH143